ALLENTOWN, Pa., July 29,
2024 /PRNewswire/ -- HNL Lab Medicine is pleased to
announce a strategic partnership with Diagnostica Stago Inc.,
marking the inauguration of the HNL Lab Medicine Strategic
Preferred Partnerships Program. This collaboration signifies a new
era of cooperative efforts aimed at addressing the evolving
challenges in the laboratory industry.
Forging a powerful partnership with a
world-class laboratory like HNL Lab Medicine empowers us both
Warren Erdmann, Chief Operating
Officer of HNL Lab Medicine, emphasized the critical need for
strong vendor partnerships in today's dynamic lab environment. "The
lab industry continues to face new challenges. Labs today cannot
face them alone and succeed without healthy, mutually beneficial
partnerships with our lab vendors. Just as we need vendors, our
vendors cannot succeed without us. It is necessary to create
comprehensive expectations in order to meet the needs of our
patients and providers. HNL Lab Medicine's Strategic Preferred
Partnership Agreement endeavors to set the standard our mutual
service must accomplish."
Stago's commitment to this initiative is underscored by its
ongoing collaboration with HNL Lab Medicine. Erdmann acknowledged
Stago's role, stating, "HNL Lab Medicine has enjoyed the pleasure
of working with the team from Stago for the past 4 years. It is no
surprise Stago is the first to sign our partnership and embrace the
principles within. HNL Lab Medicine will continue to evaluate
partners within the industry as we set a course to create a
paradigm shift in vendor partnerships."
Nichole Howard, Director of Sales
and Marketing at Stago, expressed her enthusiasm for the
partnership. "At the heart of Stago's mission is an unwavering
commitment to patient care and customer satisfaction. HNL Lab
Medicine's Strategic Partnership Agreement is thoughtfully
constructed to foster a culture of accountability, respect, and
value between the lab and its vendors – a necessity for mutual
success in today's environment. Forging a powerful partnership with
a world-class laboratory like HNL Lab Medicine empowers us both to
remain focused on delivering the labcare our health system and its
patients rely on. We will tackle challenges together,
stronger."
The HNL Lab Medicine Strategic Preferred Partnership Agreement
outlines shared expectations and principles to foster collaboration
amidst the industry's contemporary challenges. The agreement is
built on three pillars: delivering quality results, providing
exceptional service to patients and providers, and maintaining a
healthy financial model to reinvest in employees, facilities,
equipment, and service improvements. It also promotes access to
technical staff for long-term planning, partnerships for clinical
studies, collaboration with sales teams, and other mutually
beneficial opportunities.
Given the ongoing challenges faced by the lab industry, creating
and sustaining true partnerships with vendors is crucial for
success. The HNL Lab Medicine Strategic Preferred Partnership
program ensures growth and shared success with partners willing to
accept both risk and reward, fostering long-term relationships with
vendors who understand the shared path to future success. For more
information about HNL Lab Medicine or the Strategic Preferred
Partnership Program, contact us at hnl.com.
About HNL Lab Medicine
HNL Lab Medicine is a leading multi‐regional, full‐service
medical laboratory providing testing and related services to
physician offices, hospitals, long‐term care facilities, employers
and industrial accounts. With 50+ patient service centers in
Pennsylvania and 14 acute care
laboratories within partners' hospital sites, and over 40
board-certified pathologists and scientific directors, HNL Lab
Medicine provides high-quality, advanced diagnostic testing. Learn
more at HNL.com.
About Stago
International, independent, and privately-owned group
established in 1945 in France,
Stago is currently the only company in the In Vitro Diagnostics
industry exclusively dedicated to the exploration of Hemostasis and
Thrombosis.
With a staff close to 2,500 and the most advanced technologies,
Stago designs, manufactures and markets the broadest range of
reagents and analytical instruments in hemostasis worldwide. Stago
offers consistent, high-quality solutions. Stago devotes its
research and innovative skills to the development of increasingly
effective medical diagnostic products and instrumentation.
Media Contact: Jessica
Bargilione
jessica.bargilione@hnl.com
484-425-8612
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hnl-lab-medicine-announces-partnership-with-stago-and-launch-of-strategic-preferred-partnerships-program-302209010.html
SOURCE HNL Lab Medicine